Summarized by Masters of Longevity from Longevity Technology.
Analysis of a longevity biotech market model that separates a $230 billion core pipeline from a conditional $173 billion upside tied to a new gerotherapeutic regulatory category.
Key Takeaways
- Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.
- It exists inside disease categories regulators already recognize, using approval routes already walked a thousand times over.
- The $173 billion sitting on top of it is a rather different proposition.
